Toledo, OH 的 非小細胞肺癌 臨床試驗
17 項針對 非小細胞肺癌 的研究正在 Toledo（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- Mercy Health - Perrysburg Cancer Center /ID# 270536, Perrysburg · 距離 8 英里
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
招募中3 期
- ProMedica Flower Hospital, Sylvania · 距離 9 英里
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- Mercy Health - Saint Anne Hospital, Toledo
- Mercy Health - Perrysburg Hospital, Perrysburg · 距離 8 英里
- ProMedica Flower Hospital, Sylvania · 距離 9 英里
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
招募中1 期
- Site 06, Maumee · 距離 9 英里
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
招募中3 期
- Taylor Cancer Research Center, Maumee · 距離 9 英里
Pan-tumor MRD Study
招募中觀察性研究
- Taylor Cancer Research Center, Maumee · 距離 9 英里
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
招募中3 期
- Research Site, Toledo
- Research Site, Maumee · 距離 9 英里
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
招募中觀察性研究
- Toledo Clinic Cancer Center, Toledo
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
招募中2 期
- Mercy Health - Saint Anne Hospital, Toledo
- Mercy Health - Perrysburg Hospital, Perrysburg · 距離 8 英里
- ProMedica Flower Hospital, Sylvania · 距離 9 英里
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
招募中1/2 期
- Taylor Cancer Research Center, Maumee · 距離 9 英里
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- Research Site, Maumee · 距離 9 英里
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- ProMedica Flower Hospital, Sylvania · 距離 9 英里
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
招募中2/3 期
- ProMedica Flower Hospital, Sylvania · 距離 9 英里
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- ProMedica Flower Hospital, Sylvania · 距離 9 英里
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
招募中1/2 期
- Taylor Cancer Research Center, Maumee · 距離 9 英里
GEMINI-NSCLC: NSCLC Biomarker Study
招募中觀察性研究
- Taylor Cancer Research Center, Maumee · 距離 9 英里
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
招募中1/2 期
- Taylor Cancer Research Center (site 204), Maumee · 距離 9 英里
其他城市的 非小細胞肺癌 試驗
- Houston, TX145 項研究
- New York City, NY121 項研究
- Arlington, VA104 項研究
- Nashville, TN97 項研究
- Boston, MA90 項研究
- Los Angeles, CA87 項研究
- St. Louis, MO73 項研究
- Chicago, IL61 項研究
- Baltimore, MD60 項研究
- San Antonio, TX59 項研究
- Columbus, OH57 項研究
- Washington, DC55 項研究
Toledo 的其他研究
- 卵巢癌12 項研究
- 肺癌11 項研究
- 轉移性癌症10 項研究
- 中風9 項研究
- 頭頸部鱗狀細胞癌8 項研究
- 子宮內膜癌8 項研究
- 黑色素瘤8 項研究
- 胰臟癌8 項研究
- 前列腺癌7 項研究
- 食道癌7 項研究
- 缺血性中風7 項研究
- 心臟衰竭7 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。